Last Updated: February 24th, 2026
Introduction
Client aimed to launch a novel treatment in a rare hematologic disease, challenging an entrenched incumbent with strong efficacy metrics rooted in industry-standard measures. Despite Client’s drug showcasing superior efficacy and maintaining safety standards, several challenges had arisen, including issues with ROA, dosing, and frequency.
The Problem
Our client sought assistance in establishing strategic direction for their therapy pre-launch, particularly in effectively communicating its robust value to physicians and other priority stakeholders. The client lacked clarity on how to achieve their aspiration of becoming the new first-line standard of care at launch.
Our Solution
- Conducted a situation analysis to align the client’s offering with market needs and establish positioning based on clinical value versus the standard of care (SOC).
- Reset launch goals and developed a cross-functional strategy for cohesive communication, congress activities, and internal training.
- Created a strategic scientific platform and narrative to support the new goals and positioning.
- Engaged with key opinion leaders (KOLs) for insights that shaped the narrative and informed launch activities.
Value Delivered
- Aligned the client’s offering with key stakeholder insights for impactful communications and data generation.
- Shifted expectations around efficacy measures to frame the clinical data narrative effectively.
- Initiated publications on outcome measures, reinforcing the client’s clinical data story and novel MOA.
- Clarified the drug’s value for uncontrolled patients on SOC who had no alternative, versus first-line treatment.
Refine your market strategy with tailored insights
FAQs on Rare Disease Launch Strategy
-
What challenges do companies face when launching therapies in rare hematologic diseases?
Common challenges include entrenched standards of care, limited flexibility around traditional efficacy endpoints, and the need to clearly differentiate clinical value despite small patient populations. -
How can a new therapy compete with an established standard of care at launch?
Successful competition requires redefining relevant outcome measures, aligning stakeholders around a clear clinical narrative, and engaging key opinion leaders early to support differentiated positioning. -
Why are outcome measures critical for adoption in rare disease launches?
Outcome measures shape how clinical benefit is perceived. Broadening or reframing endpoints can better reflect real-world patient needs and strengthen the therapy’s value story for physicians and decision-makers.